Survivin expression in pituitary adenomas

Neuroendocrinology Letters

Volumn 26, Issue 3, 2005, Pages 209-212

  Wasko, Ryszard ^a   Jankowska, Anna ^a   Waligorska Stachura, Joanna ^a   Andrusiewicz, Miroslaw ^a   Jaskula, Magdalena ^a   Sowinski, Jerzy ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Adenomas; Pituitary; Survivin

Indexed keywords

COMPLEMENTARY DNA; LONG ACTING DRUG; MESSENGER RNA; OCTREOTIDE; SURVIVIN; TUMOR ANTIGEN;

ACROMEGALY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DNA SYNTHESIS; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS FUNCTION; MALIGNANT TRANSFORMATION; NUCLEOTIDE SEQUENCE; PREDICTION; PREOPERATIVE CARE; PROGNOSIS; PROLACTINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR CLASSIFICATION; TUMOR GROWTH;

EID: 22144491922     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998; 351(9106):882-3.
2. Adida C, Haiou C, Gaulard P, Lepage E, Morel P, Briere J et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96(5):1921-5.
3. Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol. 2000;111(1):196-203.
4. Altieri DC, Marchisio PC. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 1999; 79(11):1327-33.
5. Amato G, Mazziotti G, Rotondo M, Iorio S, Doga M, Sorvillo F et al. Long-term effects of lanreotide SR and octreotide LAR on tumor shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf).2002; 56(1):65-71.
6. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3 (8): 917-21.
7. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998; 273(18):11177-82.
8. Andersen MH, Thor SP. Survivin- a universal tumor antigen. Histol Histopathol 2002; 17(2):669-75.
9. Azuhata T, Scott D, Takamizawa S, Wen J, Davidoff A, Fukuzawa M et al. The inhibitor of apoptosis protein survivin is associated with high-risk behaviour of neuroblastoma. J Pediatr Surg 2001; 36(12):1785-91.
10. Baldelli R., Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E et al.: Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 2000; 85(11):4099-4103.
11. Buolamwini JK. Novel anticancer drug discovery. Curr Opin Chem Biol. 1999;3:500-9.
12. Caldas H, Honsey LE, Altura RA. Survivin 2a: a novel survivin splice variant expressed in malignancies. Mol Cancer 2005; 4(1):11.
13. Cannavo S, Squadrito S, Curto L, Almoto B, Trimarchi F. Effectiveness of slow-release Lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. Horm Metab Res. 2001; 618-624.
14. Cerman J, Cap J, Marekova M, Nemecek S, Marek J, Rudolf E et al. The role of apoptosis in pituitary adenomas in the field of conventionally used therapeutic approaches. Ann N Y Acad Sci. 2003; 1010:520-4.
15. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin human melanoma. J Invest Dermatol 1999; 113 (6):1076-81.
16. Harinarayan CV, Reddy K. Metastasising pituitary neuroendocrinal tumor with peptide secrection. J Assoc Physicians India. 2004; 52:74-5.
17. Horwitz GA, Miklovsky I, Heaney AP, Ren SG, Melmed S. Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression. Mol Endocrinol. 2003;17(4):600-609.
18. Kabayashi K, Hatano M, Otaki M, Ogasawara T, Tokuhisa T. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci U S A. 1999; 96(4):1457-1462.
19. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K et al. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 2003; 97(4):1077-83.
20. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58(22):5071-4.
21. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003; 362 (9379):205-9.
22. Koch CA, Vortmeyer AO, Diallo R, Poremba C, Giordano TJ, Sanders D et al. Survivin: a novel neuroendocrine marker for pheochromocytoma. Eur J Endocrinol 2002; 146(3):381-8.
23. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J,Tognin S. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1(8):461-6.
24. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-delta Ex3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999; 59:6097-102.
25. Mariani L, Schaller B, Weis J, Ozdoba C, Seiler RW. Estheioneuroblastoma of the pituitary gland: a clinicopathological entity? Case report and review of the literature. J Neurosurg 2004; 101(6):1049-52.
26. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999; 17 (7)2100-4.
27. Musat M, Vax VV, Borboli N, Gueorguiev M, Bonner S, Korbonits M et al. Cell cycle dysregulation in pituitary oncogenesis. Front Horm Res 2004; 32:34-62.
28. Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1997; 11:433-441.
29. Saeger W. Proliferation markers and cell cycle inhibitors in pituitary adenomas. Front Horm Res 2004; 32:110-26.
30. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer. 2004;100 (4): 751-757.
31. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax caspases, and anticancer drugs. Cancer Res 1998; 58 (23):5315-20.
32. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis breast carcinomas. Clin Cancer Res 2000; 6(1):127-34.
33. Wasko R, Jankowska A, Kotwicka M, Liebert W, Sowinski J, Warchol JB. Effects of treatment with somatostatin analoques on the occurrence of apoptosis in somatotropinomas. Neurendocrinol Lett. 2003; 24(5):334-8.
34. Xing N, Qian J, Bostwick D, Bergstralh E, Young CY. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 2001; 48(1):7-15.
35. Yu R., Melmed S.: Oncogene activation in pituitary tumors. Brain Pathol 2001 Jul;11 (3):328-41.
36. Zumkeller W. The role of the GH/IGF-1 system in pituitary tumorogenesis. Horm Metabol Res 2003; 664-666.